공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 올리고뉴클레오티드 치료제 시장

Oligonucleotide Therapeutics

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997520
페이지 정보 영문 176 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 올리고뉴클레오티드 치료제 시장 Oligonucleotide Therapeutics
발행일 : 2021년 04월 페이지 정보 : 영문 176 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 올리고뉴클레오티드 치료제 시장 규모는 분석기간(2020-2027년)에 8.1%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 14억 달러에서 2027년에는 25억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 신경장애는 분석기간 중 6.9%의 CAGR을 나타내고, 15억 달러에 달할 전망입니다.

세계의 올리고뉴클레오티드 치료제(Oligonucleotide Therapeutics) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Arrowhead Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.
  • Sarepta Therapeutics Inc.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 44개사
LSH 21.04.08

Abstract:

Global Oligonucleotide Therapeutics Market to Reach $2.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Oligonucleotide Therapeutics estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Neurological Disorders, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cancer segment is readjusted to a revised 11.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $426.2 Million, While China is Forecast to Grow at 7.6% CAGR

The Oligonucleotide Therapeutics market in the U.S. is estimated at US$426.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$434.4 Million by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 6.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Other Applications Segment to Record 6.1% CAGR

In the global Other Applications segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$97.7 Million in the year 2020 will reach a projected size of US$148.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$288.6 Million by the year 2027.

Select Competitors (Total 44 Featured) -

  • Arrowhead Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.
  • Sarepta Therapeutics Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Antisense/RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Antisense/RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Antisense/RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 22: USA Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 28: Canada Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 34: Japan Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 37: China Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 40: China Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 43: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 52: France Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 55: France Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 58: Germany Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 61: Germany Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 64: Italy Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 67: Italy Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 70: UK Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 73: UK Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Europe 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 79: Rest of Europe Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Europe 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 82: Asia-Pacific Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Asia-Pacific 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 85: Asia-Pacific Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Asia-Pacific 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 88: Rest of World Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of World 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 91: Rest of World Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of World 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44
Back to Top
전화 문의
F A Q